Physician profile
Roseann Benanti
NPI 1780330902
$24,296.87
in general payments reported to CMS, 2019-2025
29 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $791 · 2023: $1,228 · 2024: $1,603 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,600 · Travel and Lodging: $1,186 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,525.00 |
| Food and Beverage | $6,599.53 |
| Travel and Lodging | $1,186.05 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19,143.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $785.52 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $763.81 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $537.85 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Scientific Affairs, LLC | $443.73 | 2024-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $379.78 | 2022-2025 | Ocaliva |
| Celgene Corporation | $300.50 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $291.73 | 2023-2024 | Linzess |
| Genzyme Corporation | $241.90 | 2025 | |
| Pfizer INC. | $180.79 | 2023-2025 | |
| Daiichi Sankyo INC. | $158.38 | 2022-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $157.84 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $123.52 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $111.31 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $110.81 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $109.02 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2022 | |
| Ardelyx, INC. | $48.06 | 2022-2024 | Ibsrela |
| Organon LLC | $47.76 | 2023-2024 | Hadlima |
| Braintree Laboratories, INC. | $45.60 | 2023-2025 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $39.94 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $37.90 | 2024-2025 | Bylvay, Iqirvo |
| Ferring Pharmaceuticals INC. | $29.58 | 2023 | Rebyota |
| Qol Medical, LLC | $22.25 | 2024 | Sucraid |
| Biocon Biologics INC | $20.65 | 2025 | Yesintek |
| Boston Scientific Corporation | $17.95 | 2025 | Lithovue |
| Novo Nordisk INC | $15.69 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $13.40 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roseann Benanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.